Developments in rabies vaccines

Clinical and Experimental Immunology

Volumn 169, Issue 3, 2012, Pages 199-204

  Hicks, D J ^a   Fooks, A R ^a,b   Johnson, N ^a  

^a VETERINARY LABORATORIES AGENCY   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Central nervous system; Rabies virus; Reverse genetics; Vaccination

Indexed keywords

RABIES VACCINE; VIRUS GLYCOPROTEIN;

CANINE ADENOVIRUS; DNA IMMUNIZATION; IMMUNE RESPONSE; INFECTION PREVENTION; INNATE IMMUNITY; PRIORITY JOURNAL; RABIES; RABIES VIRUS; REVERSE GENETICS; REVIEW; VACCINATION; VIRUS GENOME;

ANIMALS; ANTIBODIES, VIRAL; BITES AND STINGS; CHIROPTERA; DISEASE RESERVOIRS; DOG DISEASES; DOGS; ENDEMIC DISEASES; GENOME, VIRAL; HUMANS; IMMUNITY, INNATE; MICE; MODELS, ANIMAL; NERVOUS SYSTEM; RABIES; RABIES VACCINES; RABIES VIRUS; VACCINATION; VACCINES, INACTIVATED; VACCINES, SYNTHETIC; WORLD HEALTH;

EID: 84864768430     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2012.04592.x     Document Type: Review

References (47)

1. Tordo N, Poch O, Ermine A etal. Completion of the rabies virus genome sequence determination: highly conserved domains among the L (polymerase) proteins of unsegmented negative-strand RNA viruses. Virology 1988; 165:565-76.
2. Sudarshan MK, Madhusudana SN, Mahendra BJ etal. Assessing the burden of human rabies in India: results of a national multi-center epidemiological survey. Int J Infect Dis 2007; 11:29-35.
3. Johnson N, Vos A, Freuling C etal. Human rabies due to lyssavirus infection of bat origin. Vet Microbiol 2010; 142:151-9.
4. Badrane H, Tordo N. Host switching in lyssavirus history from the Chiroptera to the Carnivora orders. J Virol 2001; 75:8096-104.
5. Messenger SL, Smith JS, Rupprecht CE. Emerging epidemiology of bat-associated cryptic cases of rabies in humans in the United States. Clin Infect Dis 2002; 35:738-47.
6. De Serres G, Dallaire F, Côte M, Skowronski M. Bat rabies in the United States and Canada from 1950 through 2007: human cases with and without bat contact. Clin Infect Dis 2008; 46:1329-37.
7. Schnell MJ, McGettigan JP, Wirblich C, Papaneri A. The cell biology of rabies virus: using stealth to reach the brain. Nat Rev Microbiol 2010; 8:51-61.
8. Hicks DJ, Nunez A, Healy DM etal. Comparative pathological study of the murine brain after experimental infection with classical rabies virus and European bat lyssavirus. J Comp Pathol 2009; 140:113-26.
9. Hooper DC, Morimoto K, Bettle M etal. Collaboration of antibody and inflammation in clearance of rabies virus from the central nervous system. J Virol 1998; 72:3711-9.
10. Hunter M, Johnson N, Hedderwick S etal. Immunovirological correlates in human rabies treated with therapeutic coma. J Med Virol 2010; 82:1255-65.
11. Dacheux L, Delmas O, Bourhy H. Human rabies encephalitis prevention and treatment: progress since Pasteur's discovery. Infect Disord Drug Targets 2011; 11:251-99.
12. Wu X, Smith TG, Rupprecht CE. From brain passage to cell adaptation: the road of human rabies vaccine development. Exp Rev Vaccines 2011; 10:1597-608.
13. Bardenave G. Louis Pasteur (1822-1895). Microbes Infect 2003; 5:553-60.
14. Fermi C. Über die Immunisierung gegen Wutkrankheit. [Immunisation against rabies.] Z Hyg Infectionskrankh 1908; 58:233-76.
15. Semple D. The preparation of a safe and efficient antirabic vaccine. Sci Mem Med Sanit Dept India 1911; 44:1-31.
16. Koprowski H, Cox HR. Studies on chick embryo adapted rabies virus: I. Culture characteristics and pathogenicity. J Immunol 1948; 60:533-54.
17. Fuenzalida E, Palacios R, Borgono JM. Anti-rabies antibody responses in man to vaccine made from infected suckling-mouse brains. Bull World Health Organ 1964; 30:431-6.
18. Kissling RE. Growth of rabies virus in non-nervous tissue. Proc Soc Exp Biol Med 1958; 98:223-5.
19. Kissling RE, Reese DR. Anti-rabies vaccine of tissue culture origin. J Immunol 1963; 91:362-8.
20. Flamand A, Coulon P, Lafay F, Tuffereau C. Avirulent mutants of rabies virus and their use as live vaccine. Trends Microbiol 1993; 1:317-20.
21. Wiktor TJ, Fernandes MV, Koprowski H. Cultivation of rabies virus in human diploid cell strain WI-38. J Immunol 1964; 93:353-66.
22. Kondo A. Growth characteristics of rabies virus in primary chicken embryo cells. Virology 1965; 27:199-204.
23. Morris J, Crowcroft NS, Fooks AR etal. Rabies antibody levels in bat handlers in the United Kingdom: immune response before and after purified chick embryo cell rabies booster vaccination. Hum Vaccin 2007; 3:165-70.
24. Verma R, Khanna P, Prinja S, Rajput M. Intra-dermal administration of rabies vaccines in developing countries: at an affordable cost. Hum Vaccin 2011; 7:792-4.
25. Gueu L, Schares S, Schinck C etal. Genetic characterisation of attenuated SAD rabies virus strains used for oral vaccination of wildlife. Vaccine 2008; 26:3227-35.
26. Cliquet F, Aubert M. Elimination of terrestrial rabies in Western European countries. Dev Biol 2004; 119:185-204.
27. Vos A, Freuling C, Eskiizmirliler S etal. Rabies in foxes, Aegean Region, Turkey. Emerg Infect Dis 2009; 15:1620-2.
28. Seif I, Coulon P, Rollin PE, Flamand A. Rabies virulence: effect on pathogenicity and sequence characterisation of rabies virus mutations affecting antigenic site III of the glycoprotein. J Virol 1985; 53:926-34.
29. Prehaud C, Coulon P, Lafay F etal. Antigenic site II of rabies virus glycoprotein: structure and role in viral virulence. J Virol 1988; 62:1-7.
30. Wiktor TJ, Macfarlan RI, Reagan KJ etal. Protection from rabies by a vaccinia virus recombinant containing the rabies virus glycoprotein gene. Proc Natl Acad Sci USA 1984; 81:7194-8.
31. Cadoz M, Strady A, Meignier B etal. Immunisation with canary pox virus expressing rabies glycoprotein. Lancet 1992; 339:1429-32.
32. Yarosh OK, Wandeler AI, Graham FL etal. Human adenovirus type 5 vectors expressing rabies glycoprotein. Vaccine 1996; 14:1257-564.
33. Jallet C, Jacob Y, Bahloul C etal. Chimeric lyssavirus glycoproteins with increased immunological potential. J Virol 1999; 73:225-33.
34. Lodmell DL, Ewalt LC. Post-exposure DNA vaccination protects mice against rabies virus. Vaccine 2001; 19:2468-73.
35. Conzelmann KK, Schnell M. Rescue of synthetic genome RNA analogs of rabies virus by plasmid encoded proteins. J Virol 1994; 68:713-9.
36. Willoughby RE, Tieves KS, Hoffman GM etal. Survival after treatment of rabies with induction of coma. N Engl J Med 2005; 352:2508-14.
37. McDermid RC, Sacinger L, Lee B etal. Human rabies encephalitis following bat exposure: failure of therapeutic coma. Can Med Assoc J 2008; 178:557-61.
38. Wang ZH, Sarmento L, Wang Y etal. Attenuated rabies virus activities, while pathogenic rabies virus evades the host innate immune responses in the central nervous system. J Virol 2005; 79:12554-65.
39. McKimmie CS, Johnson N, Fooks AR, Fazakerley JK. Viruses selectively upregulate Toll-like receptors in the central nervous system. Biochem Biophys Res Commun 2005; 336:925-33.
40. Johnson N, Mansfield KL, Hicks D etal. Inflammatory responses in the nervous system of mice infected with a street isolate of rabies virus. Dev Biol 2008; 131:65-72.
41. Vidy A, Chelbi-Alix M, Blondel D. Rabies virus P protein interacts with STAT 1 and inhibits interferon signal transduction. J Virol 2005; 79:14411-20.
42. Brzozka K, Finke S, Conzelmann KK. Inhibition of interferon signalling by rabies virus phosphoprotein P: activation-dependent binding of STAT1 and STAT2. J Virol 2006; 80:2675-83.
43. Wen Y, Wang H, Wu H etal. Rabies virus expressing dendritic cell-activating molecules enhances the innate and adaptive immune response to vaccination. J Virol 2011; 85:1634-44.
44. Faber M, Dietzschold B, Li J. Immunogenicity and safety of recombinant rabies viruses used for oral vaccination of stray dogs and wildlife. Zoonoses Public Health 2009; 56:262-9.
45. Faber M, Pumanausakahul R, Hodawadekar SS etal. Overexpression of the rabies virus glycoprotein results in enhancement of apoptosis and antiviral immune response. J Virol 2002; 76:3374-81.
46. Faul EJ, Wanjalla CN, McGettigan JP, Schnell MJ. Interferon-β expressed by a rabies virus-based HIV-1 vaccine vector serves as a molecular adjuvant and decreases pathogenicity. Virology 2008; 382:226-38.
47. Zhao L, Toriumi H, Wang H etal. Expression of MIP-1alpha (CCL3) by a recombinant rabies virus enhances its immunogenicity by inducing innate immunity and recruiting dendritic cells and B cells. J Virol 2010; 84:9642-8.